Primidone

From WikiMD's WELLNESSPEDIA

(Redirected from Liskantin)

Primidone is an aromatic anticonvulsant used to treat complex, partial and generalized seizures. 


Liver safety of Primidone[edit]

Therapy with primidone can be associated with increases in gamma glutamyltranspeptidase levels, but is not associated with serum aminotransferase elevations, and despite its similarity in structure to phenobarbital and phenytoin, clinically apparent liver injury from primidone has not been reported and must be exceedingly rare if it occurs at all.


Mechanism of action of Primidone[edit]

Primidone (prim' i done) is a pyrimidinedione anticonvulsant and is partially metabolized to phenobarbital.  Primidone is effective in suppressing seizure activity, but its mechanism of action is not well defined.  It is believed to work centrally via interactions with voltage-gated sodium channels inhibiting repetitive firing of action potentials. 

FDA approval information for Primidone[edit]

Primidone was approved for use in epilepsy in the United States in 1954.  For many years, primidone was considered a first line anticonvulsant agent, but it has been largely replaced by more recently developed anticonvulsants that are better tolerated, less sedative and have fewer long term adverse side effects.  Primidone has also been used to treat essential tremor. 

Dosage and administration for Primidone[edit]

Primidone is available as tablets of 50 and 250 mg in several generic formulations and under the brand names Mysoline, Myidone, Sertan and Apo-Primidone.  The recommended initial dose for adults is 100 to 125 mg daily, increasing slowly to a maintenance dose of 250 mg three times daily. 

Side effects of Primidone[edit]

The most common side effects are dose related and include drowsiness, ataxia, diplopia, and headache.  The initial dose may be associated with an acute toxic reaction with nausea, malaise, sedation, ataxia and confusion.  Long term therapy may be associated with megaloblastic anemias and birth defects.



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.